Syneron Medical Earnings: Everything You Must Know Now

Syneron Medical Ltd. (NASDAQ:ELOS) delivered a profit and met Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Syneron Medical Ltd. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share were the same at $0.02 in the quarter as EPS of $0.02 in the year-earlier quarter.

Revenue: Decreased 2.33% to $61.2 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Syneron Medical Ltd. reported adjusted EPS income of $0.02 per share. By that measure, the company met the mean analyst estimate of $0.02. It beat the average revenue estimate of $61.19 million.

Quoting Management: Dr. Shimon Eckhouse, Chief Executive Officer of Syneron, commented, “In the PAD segment, revenue was down 5%, while in the EBU segment we achieved another quarter of record revenue. Although the basic demand for our products and technologies on a global basis remains strong, we have some areas in which we are implementing new strategies to drive growth and profitability. On the revenue side, we saw moderate PAD segment growth in all geographies except for EMEA and Japan, which were impacted by macroeconomic conditions. There continues to be strong interest in our recently launched products, including at several major industry conferences during the quarter. We remain on track with our UltraShape U.S. clinical trial and recently introduced several enhancements to our body shaping product portfolio. We have begun making strategic additions to our U.S. sales team to target the gradually recovering economy, including the non-core market, along with selective resource reallocations within our global team to focus on high demand geographies. This will support operating margin expansion as we grow revenue and further optimize our operating infrastructure.”

Key Stats (on next page)…

Revenue decreased 15.89% from $72.76 million in the previous quarter. EPS decreased 81.82% from $0.11 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.14 to a profit $0.12. For the current year, the average estimate has moved down from a profit of $0.59 to a profit of $0.47 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]